<DOC>
	<DOCNO>NCT00915252</DOCNO>
	<brief_summary>The primary purpose study determine , whether addition 5-azacytidine standard chemotherapy elderly patient newly diagnose AML improve treatment result ( event free survival ) .</brief_summary>
	<brief_title>Efficacy 5-azacytidine Added Standard Primary Therapy Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients newly diagnose AML ( except APL ) accord FAB WHO classification , include AML evolve MDS hematological disease AML previous cytotoxic therapy radiation ( secondary AML ) . Bone marrow aspirate biopsy must contain ≥ 20 % blast nucleate cell differential blood count must contain ≥ 20 % blast . In AML FAB M6 ≥ 30 % nonerythroid cell bone marrow must leukemic blast . In AML define cytogenetic aberration proportion blast may &lt; 20 % . Age ≥ 61 year Informed consent , personally sign date participate study Male patient enrol trial must use adequate barrier birth control measure course 5azacytidine treatment least 3 month last administration 5azacytidine . Patients eligible standard chemotherapy describe chapter 5.2 5.3 Hyperleukocytosis ( leukocytes &gt; 20,000/µl ) study entry . These patient treat hydroxyurea receive leukocytapheresis treatment ( leukocytes &gt; 100,000/µl ) accord routine practice enter study leukocyte count 20,000/µl reach . This applies control part study . Patients initial hyperleukocytosis 20,000/µl enrol control part study , runin dose find part . Known central nervous system manifestation AML Cardiac Disease : Heart failure NYHA class 3 4 ; unstable coronary artery disease ( MI 6 month prior study entry permit ) ; serious cardiac ventricular arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Chronically impaired renal function ( creatinin clearance &lt; 30 ml / min ) Inadequate liver function ( ALT AST ≥ 2.5 x ULN ) cause leukemic infiltration Total bilirubin ≥ 1.5 x ULN cause leukemic infiltration Known HIV and/or hepatitis C infection Evidence history severe nonleukemia associate bleed diathesis coagulopathy Evidence recent history CNS disease , include primary metastatic brain tumor , seizure disorder Uncontrolled active infection Concurrent malignancy AML estimate life expectancy less two year History organ allograft Hypersensitivity cytarabine ( include drug fever exanthema ) , daunorubicin , azacytidine mannitol Previous treatment AML except hydroxyurea 2 day ≤100 mg/m2/d cytarabine Previous therapy 5azacytidine ( i.e . antecedent myelodysplastic syndrome ) Patients investigational drug therapy outside trial within 4 week study entry discuss study office whether study participation possible Any severe concomitant condition , make undesirable patient participate study could jeopardize compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>azacitidine</keyword>
	<keyword>elderly</keyword>
	<keyword>demethylating agent</keyword>
	<keyword>flt3</keyword>
	<keyword>AML</keyword>
</DOC>